INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 177 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $25,451,487 | +111.2% | 488,606 | +156.8% | 0.08% | +88.1% |
| Q2 2023 | $12,049,986 | +67.6% | 190,303 | +43.3% | 0.04% | +61.5% |
| Q1 2023 | $7,191,716 | +169276.3% | 132,811 | +65.5% | 0.03% | +73.3% |
| Q4 2022 | $4,246 | -99.8% | 80,228 | +69.2% | 0.02% | +87.5% |
| Q3 2022 | $2,207,000 | -1.3% | 47,422 | +21.0% | 0.01% | 0.0% |
| Q2 2022 | $2,237,000 | -60.6% | 39,190 | -57.7% | 0.01% | -50.0% |
| Q1 2022 | $5,672,000 | -15.4% | 92,700 | -27.6% | 0.02% | -15.8% |
| Q4 2021 | $6,705,000 | -5.1% | 128,111 | -38.5% | 0.02% | -34.5% |
| Q1 2021 | $7,068,000 | +9.0% | 208,301 | +2.1% | 0.03% | +3.6% |
| Q4 2020 | $6,487,000 | -46.9% | 203,988 | -57.1% | 0.03% | -58.8% |
| Q3 2020 | $12,211,000 | +78.3% | 475,894 | +78.4% | 0.07% | +54.5% |
| Q2 2020 | $6,847,000 | +204.9% | 266,751 | +82.5% | 0.04% | +144.4% |
| Q1 2020 | $2,246,000 | +245.5% | 146,139 | +671.4% | 0.02% | +350.0% |
| Q4 2019 | $650,000 | – | 18,945 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |